Covid19 Clinical Trial
Official title:
The ESPERES Prospective Cohort of Healthcare Workers in France: Study on the Impact of a Chatbot on COVID-19 Vaccine Perceptions and Intentions
Verified date | June 2022 |
Source | Assistance Publique - Hôpitaux de Paris |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Vaccine hesitancy also concerns healthcare workers (HCWs). However, HCWs are at the frontline of the COVID-19 pandemic and identified as a priority target group for COVID-19 vaccines. Thus, the identification of interventions likely to improve COVID-19 vaccine attitudes and intentions among HCWs is of interests to increase the vaccine coverage among HCWs. The study hypothesis is that the use of the same chatbot as the one tested in the general population in France could also improve the COVID-19 vaccine intentions and perceptions in HCWs.
Status | Completed |
Enrollment | 200 |
Est. completion date | October 15, 2021 |
Est. primary completion date | September 23, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility | Inclusion Criteria: - Legal age - Healthcare workers defined as individuals who currently work in a setting where individuals receive healthcare (i.e. individuals do not have to work directly with patients, but may have any role within a setting where individuals receive healthcare, such as administrative office, housekeeping, food service, etc.) - Included in ESPERES cohort and with the initial questionnaire completed - Agreeing to participate (digital consent) Exclusion Criteria: - No internet access - Vaccinated against COVID-19 (at least one dose) |
Country | Name | City | State |
---|---|---|---|
France | Pitié-Salpêtrière - Charles Foix, AP-HP | Paris | ILE DE France |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The change in the COVID-19 vaccine perceptions (5 questions) using a seven-point Likert scale, immediately after the access to the intervention | "I think vaccines against COVID-19 are safe"
"I think vaccines against COVID-19 are effective" "I think we know enough about the COVID-19 vaccines" "I think we can trust the people who produce the COVID-19 vaccines" "I think it is important to get vaccinated against COVID-19". The COVID-19 vaccine perceptions variable is the mean of the response to these five questions, each answered on a 7-point likert scale. |
Change from baseline to immediately after intervention (experimental or control arm) | |
Secondary | The change in the COVID-19 vaccine perceptions (5 questions) using a seven-point Likert scale, 15-days after the access to the intervention | "I think vaccines against COVID-19 are safe"
"I think vaccines against COVID-19 are effective" "I think we knowenough about theCOVID-19 vaccines" "I think we can trust the people who produce the COVID-19 vaccines" "I think it is important to get vaccinated against COVID-19". The COVID-19 vaccine perceptions variable is the mean of the response to these five questions, each answered on a 7-point likert scale. |
From baseline to day 15 | |
Secondary | The change in the COVID-19 vaccine intention, immediately after the access to the intervention with the following question: "Do you personally intent to be vaccinated against COVID-19?" | yes, as soon as possible
yes but I prefer to wait no |
From baseline to immediately after the intervention (experimental or control arm) | |
Secondary | The change in the COVID-19 vaccine intention, 15 days after the access to the intervention with the following question: "Do you personally intent to be vaccinated against COVID-19?" (yes, as soon as possible / yes but I prefer to wait / no) | yes, as soon as possible
yes but I prefer to wait no |
From baseline to day 15 after the intervention (experimental or control arm) | |
Secondary | Changes into the attitudes and intention towards the COVID-19 vaccines according to the vaccine immediately and 15-days after the access to the interventions | Changes in self-reported attitudes and intention towards the COVID-19 vaccines | Up to 15 days | |
Secondary | Participants in the Chatbot intervention will be ask, after the access to the intervention, to answer to a satisfaction questionnaire | Participants in the Chatbot intervention will be asked whether they had been able to access the chatbot, whether the Chatbot was intuitive, pleasant, frustrating, whether the information provided in the chatbot were too simple or too complicated, and whether they had unanswered questions that they wish the chatbot had addressed (free text entry). | End of baseline questionnaire |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |